Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Income Before Tax

Profit after all operating and non-operating items but before income tax.

Caribou Biosciences, Inc.NASDAQ: CRBU

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$25.09M, compared with -$39.99M a year earlier. Trailing-twelve-month income before tax was -$133.77M.

Context

  • Income before tax amounted to 1332.3% of revenue in FY2025, down 159.7 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$25.09M or moves back toward the trailing-twelve-month quarterly average of -$33.44M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$25.09M+7.2% QoQ
Last fiscal yearDec 2025
-$148.68M+0.3% YoY
LTMMar 2026
-$133.77M+9.5% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.3%——
1 year+0.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(148.68M) USD
Year-over-year change
+0.3%

Income Before Tax vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9.5% is the 7th highest of 11, against a peer median of +17.6%.
  • Income before tax amounts to 1194.0% of revenue for CRBU, versus a peer median of 522.6%.
CRBU Competitors
Income Before Tax for CRBU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$54.64M USD+17.6%—167.0%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$61.89M USD+37.4%—89.4%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026-$69.87M USD-152.1%——
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-$75.32M USD+6.4%—266.9%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-$77.8M USD+39.1%—465.3%
PYXSPyxis Oncology, Inc.LTM Mar 2026-$80.35M USD+17.5%—579.8%
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$83.01M USD+21.5%—36891.1%
HUMAHumacyte, Inc.LTM Mar 2026-$97.59M USD-25.7%—4840.8%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$133.77M USD+9.5%—1194.0%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$173.76M USD+31.0%——
IVAInventiva S.A.FY2025-€342.33M EUR-86.1%—7636.1%
Peer median (excluding CRBU) —+17.6%—522.6%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.6M13.85M34.48M9.99M11.16M
Cost of Revenue984K3.64M3.53M3.93M3.65M
Gross Profit8.61M10.21M30.95M6.07M7.51M
Gross Margin89.7%73.7%89.8%60.7%67.3%
Research & Development52.26M82.23M112.08M130.15M109.44M
Selling, General & Admin23.34M38.02M38.46M46.46M37.91M
Operating Expenses75.59M116.61M147.01M172.68M143.71M
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
EBITDA(65.61M)(95.71M)(98.35M)(145.19M)(145.03M)
EBITDA Margin-683.6%-691.0%-285.3%-1452.7%-1299.7%
Operating Income(66.98M)(106.4M)(116.06M)(166.62M)(136.19M)
Operating Margin-697.8%-768.2%-336.6%-1667.2%-1220.5%
Interest Income148K4.6M10.7M08M
Interest Expense8K0000
Other Income / Expenses377K7.05M14.18M17.5M(12.48M)
Income Before Tax(66.6M)(99.35M)(101.88M)(149.11M)(148.68M)
Pre-Tax Margin-693.9%-717.3%-295.5%-1492.0%-1332.3%
Income Tax Expense321K70K193K(9K)(550K)
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Net Margin-697.3%-717.8%-296.1%-1491.9%-1327.4%
EPS (Basic)(1.11)(1.64)(1.38)(1.65)(1.59)
EPS (Diluted)(1.11)(1.64)(1.38)(1.65)(1.59)
Weighted Avg Shares60.26M60.8M73.81M90.32M93.39M
Weighted Avg Shares (Diluted)60.26M60.8M73.81M90.32M93.39M

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.